Who are IIV4 and PPV23's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, Bivalent OPV 2 week interval, Co-administration of MMR/YF, Havrix+Havrix, Hib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iiv4-and-ppv23.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IIV4 and PPV23 — Competitive Intelligence Brief

IIV4 and PPV23 (IIV4 and PPV23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

IIV4 and PPV23 (IIV4 and PPV23) — China National Biotec Group Company Limited. IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IIV4 and PPV23 TARGET	IIV4 and PPV23	China National Biotec Group Company Limited	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Bivalent OPV 2 week interval	Bivalent OPV 2 week interval	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	vaccine
Co-administration of MMR/YF	Co-administration of MMR/YF	Alba Maria Ropero	marketed	vaccine
Havrix+Havrix	Havrix+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
Hib	hib	Pfizer	marketed	bacterial vaccine	Haemophilus influenzae type b

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IIV4 and PPV23 — Competitive Intelligence Brief. https://druglandscape.com/ci/iiv4-and-ppv23. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab